Effects of arsenate and ergot alkaloid compounds on prostacyclin synthesis in human umbilical endothelium.
Cultured human umbilical endothelium was incubated with various concentrations of o-arsenilic acid and ergotamine tartrate respectively for 72 hr at 37 degrees C, 5% CO2/95% air in 100% humidity. At the end of incubation, medium was removed for the determination of 6-keto-PGF1 alpha concentration by RIA method. Compared to the normal controls, arsenate (0.1 to 10.0uM) showed inhibition (17 to 24%) on the PGI2 production. Ergotamine tartrate gave an activatory effect (20 to 12%) in low concentration (0.1 to 1.0uM) incubation, but had inhibitory effect (25%) on the PGI2 production in higher concentration incubation (10.0uM). These results indicate arsenate in low and high concentrations does not play an important role on prostacyclin synthesis in human umbilical endothelium. However, ergotamine tartrate at higher concentration might be a main factor for the lower prostacyclin synthesis in Blackfoot disease, an endemic disease of the peripheral vascular system found in the southwest coast of Taiwan.
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D001149:Arsenates / Q000494:pharmacology*; D001151:Arsenic / Q000494:pharmacology*; D002478:Cells, Cultured; D004727:Endothelium / Q000187:drug effects* / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis*; D004878:Ergotamine / Q000494:pharmacology*; D006801:Humans; D013919:Thromboangiitis Obliterans / Q000139:chemically induced; D014471:Umbilical Veins
D001149:Arsenates; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D001151:Arsenic; C025657:arsenic acid; D004878:Ergotamine